{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T12:48:32Z","timestamp":1791809312177,"version":"4.3.4"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,3,27]],"date-time":"2019-03-27T00:00:00Z","timestamp":1553644800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1007\/s40257-019-00432-y","type":"journal-article","created":{"date-parts":[[2019,3,27]],"date-time":"2019-03-27T20:14:17Z","timestamp":1553717657000},"page":"483-491","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Active Tuberculosis in Patients with Psoriasis Receiving Biologic Therapy: A Systematic Review"],"prefix":"10.1007","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7126-2193","authenticated-orcid":false,"given":"Igor","family":"Snast","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Einav","family":"Bercovici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efrat","family":"Solomon-Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomer","family":"Avni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorit","family":"Shitenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmilia","family":"Hodak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lev","family":"Pavlovsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,27]]},"reference":[{"key":"432_CR1","doi-asserted-by":"publisher","first-page":"e1002152","DOI":"10.1371\/journal.pmed.1002152","volume":"13","author":"RMGJ Houben","year":"2016","unstructured":"Houben RMGJ, Dodd PJ. The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling. PLoS Med. 2016;13:e1002152.","journal-title":"PLoS Med."},{"key":"432_CR2","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/sj.jidsymp.5650027","volume":"12","author":"PL Lin","year":"2007","unstructured":"Lin PL, Plessner HL, Voitenok NN, Flynn JL. Tumor necrosis factor and tuberculosis. J Investig Dermatol Symp Proc. 2007;12:22\u20135.","journal-title":"J Investig Dermatol Symp Proc."},{"key":"432_CR3","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jaad.2018.06.057","volume":"80","author":"SB Kaushik","year":"2019","unstructured":"Kaushik SB, Lebwohl MG. Psoriasis: which therapy for which patient: psoriasis comorbidities and preferred systemic agents. J Am Acad Dermatol. 2019;80:27\u201340.","journal-title":"J Am Acad Dermatol."},{"key":"432_CR4","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1002\/art.24632","volume":"60","author":"F Tubach","year":"2009","unstructured":"Tubach F, Salmon D, Ravaud P, Allanore Y, Goupille P, Br\u00e9ban M, et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum. 2009;60:1884\u201394.","journal-title":"Arthritis Rheum."},{"key":"432_CR5","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.jaad.2008.03.023","volume":"59","author":"SD Doherty","year":"2008","unstructured":"Doherty SD, Van Voorhees A, Lebwohl MG, Korman NJ, Young MS, Hsu S, et al. National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents. J Am Acad Dermatol. 2008;59:209\u201317.","journal-title":"J Am Acad Dermatol."},{"key":"432_CR6","doi-asserted-by":"publisher","first-page":"541","DOI":"10.17235\/reed.2016.4440\/2016","volume":"108","author":"S Riestra","year":"2016","unstructured":"Riestra S, de Francisco R, Arias-Guill\u00e9n M, Saro C, Garc\u00eda-Alvarado M, Duque JM, et al. Risk factors for tuberculosis in inflammatory bowel disease: anti-tumor necrosis factor and hospitalization. Rev Esp Enferm Dig. 2016;108:541\u20139.","journal-title":"Rev Esp Enferm Dig."},{"key":"432_CR7","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.ad.2018.03.013","volume":"109","author":"P Rodr\u00edguez-Jim\u00e9nez","year":"2018","unstructured":"Rodr\u00edguez-Jim\u00e9nez P, Mir-Viladrich I, Chicharro P, Solano-L\u00f3pez G, L\u00f3pez-Longo FJ, Taxonera C, et al. Prevention and treatment of tuberculosis infection in candidates for biologic therapy: a multidisciplinary consensus statement adapted to the dermatology patient. Actas Dermosifiliogr. 2018;109:584\u2013601.","journal-title":"Actas Dermosifiliogr."},{"key":"432_CR8","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jcms.2010.11.001","volume":"39","author":"K Knobloch","year":"2011","unstructured":"Knobloch K, Yoon U, Vogt PM. Preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement and publication bias. J Craniomaxillofac Surg. 2011;39:91\u20132.","journal-title":"J Craniomaxillofac Surg."},{"key":"432_CR9","doi-asserted-by":"publisher","first-page":"2234","DOI":"10.1097\/PRS.0b013e3181f44abc","volume":"126","author":"JW Song","year":"2010","unstructured":"Song JW, Chung KC. Observational studies: cohort and case-control studies. Plast Reconstr Surg. 2010;126:2234\u201342.","journal-title":"Plast Reconstr Surg."},{"key":"432_CR10","doi-asserted-by":"crossref","unstructured":"Diagnostic standards and classification of tuberculosis in adults and children. Am J Respir Crit Care Med. 2000;161:1376\u201395.","DOI":"10.1164\/ajrccm.161.4.16141"},{"key":"432_CR11","unstructured":"WHO estimates of tuberculosis incidence by country 2014 v2.pdf [Internet]. [cited 2019 Jan 30]. https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/491527\/WHO_estimates_of_tuberculosis_incidence_by_country__2014_v2.pdf ."},{"key":"432_CR12","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/S0002-9343(02)01205-6","volume":"113","author":"EN Liberopoulos","year":"2002","unstructured":"Liberopoulos EN, Drosos AA, Elisaf MS. Exacerbation of tuberculosis enteritis after treatment with infliximab. Am J Med. 2002;113:615.","journal-title":"Am J Med."},{"key":"432_CR13","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1093\/rheumatology\/keg158","volume":"42","author":"JC Taylor","year":"2003","unstructured":"Taylor JC, Orkin R, Lanham J. Tuberculosis following therapy with infliximab may be refractory to antibiotic therapy. Rheumatol Oxf Engl. 2003;42:901\u20132.","journal-title":"Rheumatol Oxf Engl."},{"key":"432_CR14","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1136\/ard.62.9.829","volume":"62","author":"D Baeten","year":"2003","unstructured":"Baeten D, Kruithof E, Van den Bosch F, Van den Bossche N, Herssens A, Mielants H, et al. Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease? Ann Rheum Dis. 2003;62:829\u201334.","journal-title":"Ann Rheum Dis."},{"key":"432_CR15","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1111\/j.1365-2133.2006.07316.x","volume":"155","author":"CH Smith","year":"2006","unstructured":"Smith CH, Jackson K, Bashir SJ, Perez A, Chew AL, Powell AM, et al. Infliximab for severe, treatment-resistant psoriasis: a prospective, open-label study. Br J Dermatol. 2006;155:160\u20139.","journal-title":"Br J Dermatol."},{"key":"432_CR16","first-page":"1127","volume":"10","author":"L Sichletidis","year":"2006","unstructured":"Sichletidis L, Settas L, Spyratos D, Chloros D, Patakas D. Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis. Int J Tuberc Lung Dis. 2006;10:1127\u201332.","journal-title":"Int J Tuberc Lung Dis."},{"key":"432_CR17","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1111\/j.1365-2133.2009.09331.x","volume":"161","author":"E Laffitte","year":"2009","unstructured":"Laffitte E, Janssens JP, Roux-Lombard P, Thielen AM, Barde C, Marazza G, et al. Tuberculosis screening in patients with psoriasis before antitumour necrosis factor therapy: comparison of an interferon-gamma release assay vs. tuberculin skin test. Br J Dermatol. 2009;161:797\u2013800.","journal-title":"Br J Dermatol."},{"key":"432_CR18","doi-asserted-by":"crossref","first-page":"11","DOI":"10.5070\/D31HD646HW","volume":"15","author":"G Kitamura","year":"2009","unstructured":"Kitamura G, Mehr N, Anderson N, Sirichotiratana M. A case of tuberculosis in a patient on efalizumab and etanercept for treatment of refractory palmopustular psoriasis and psoriatic arthritis. Dermatol Online J. 2009;15:11.","journal-title":"Dermatol Online J."},{"key":"432_CR19","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/j.1365-2133.2008.08891.x","volume":"160","author":"A Perlmutter","year":"2009","unstructured":"Perlmutter A, Mittal A, Menter A. Tuberculosis and tumour necrosis factor-alpha inhibitor therapy: a report of three cases in patients with psoriasis. Comprehensive screening and therapeutic guidelines for clinicians. Br J Dermatol. 2009;160:8\u201315.","journal-title":"Br J Dermatol."},{"issue":"Suppl 1","key":"432_CR20","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2165\/1153421-S0-000000000-00000","volume":"11","author":"R Huo","year":"2010","unstructured":"Huo R, Romanelli P. Etanercept therapy for psoriasis in a patient with active pulmonary tuberculosis. Am J Clin Dermatol. 2010;11(Suppl 1):39\u201340.","journal-title":"Am J Clin Dermatol."},{"key":"432_CR21","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1002\/acr.20245","volume":"62","author":"T Racunica","year":"2010","unstructured":"Racunica T, Cassidy D, Cicuttini F, Hall A. Trouble with tumor necrosis factor alpha inhibitors, not just tuberculosis. Arthritis Care Res. 2010;62:770\u20134.","journal-title":"Arthritis Care Res."},{"issue":"Suppl 1","key":"432_CR22","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1111\/j.1529-8019.2009.01278.x","volume":"23","author":"A Gori","year":"2010","unstructured":"Gori A, Fabroni C, Prignano F, Lotti T. Unusual presentation of tuberculosis in an infliximab-treated patient\u2014which is the correct TB screening before starting a biologic? Dermatol Ther. 2010;23(Suppl 1):S1\u20133.","journal-title":"Dermatol Ther."},{"key":"432_CR23","first-page":"553","volume":"164","author":"H-Y Chiu","year":"2011","unstructured":"Chiu H-Y, Hsueh P-R, Tsai T-F. Clinical experience of QuantiFERON(\u00ae)-TB Gold testing in patients with psoriasis treated with tumour necrosis factor blockers in Taiwan. Br J Dermatol. 2011;164:553\u20139.","journal-title":"Br J Dermatol."},{"key":"432_CR24","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1111\/j.1468-3083.2010.03836.x","volume":"25","author":"AI S\u00e1nchez-Moya","year":"2011","unstructured":"S\u00e1nchez-Moya AI, Dauden E. Incidence of tuberculosis infection in psoriatic patients on anti-TNF therapy: report of a case series with 144 patients. J Eur Acad Dermatol Venereol. 2011;25:730\u20133.","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"432_CR25","first-page":"120","volume":"90","author":"N Skroza","year":"2012","unstructured":"Skroza N, Proietti I, Bernardini N, La Viola G, Nicolucci F, Tolino E, et al. Severe psoriasis with positive tuberculosis test and treatment with biologic therapy: a case report. Cutis. 2012;90:120\u20132.","journal-title":"Cutis."},{"key":"432_CR26","doi-asserted-by":"publisher","first-page":"401","DOI":"10.3109\/03009742.2012.676063","volume":"41","author":"M Psichogiou","year":"2012","unstructured":"Psichogiou M, Sfikakis PP, Kontos F, Daikos GL. Tuberculosis after anti-TNF therapy: a continuous learning process. Scand J Rheumatol. 2012;41:401\u20133.","journal-title":"Scand J Rheumatol."},{"key":"432_CR27","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.3899\/jrheum.111577","volume":"39","author":"BW Teh","year":"2012","unstructured":"Teh BW, Street AC, McBryde ES, Denholm JT. Miliary tuberculosis following negative latent tuberculosis infection screening prior to tumor necrosis factor-\u03b1 antagonists: implications for management? J Rheumatol. 2012;39:1297\u20138.","journal-title":"J Rheumatol."},{"key":"432_CR28","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1159\/000337145","volume":"4","author":"SA Shaikha","year":"2012","unstructured":"Shaikha SA, Mansour K, Riad H. Reactivation of tuberculosis in three cases of psoriasis after initiation of anti-TNF therapy. Case Rep Dermatol. 2012;4:41\u20136.","journal-title":"Case Rep Dermatol."},{"key":"432_CR29","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1016\/j.amjmed.2012.02.006","volume":"125","author":"C Moureau","year":"2012","unstructured":"Moureau C, Pothen L, Wilmes D, Yombi JC, Coche E, Hainaut P. Paradoxical response to tuberculosis treatment in a patient receiving tumor necrosis factor-alpha antagonist. Am J Med. 2012;125:e9\u201310.","journal-title":"Am J Med."},{"key":"432_CR30","first-page":"119","volume":"11","author":"PR Letada","year":"2012","unstructured":"Letada PR, Hitchcock E, Steele SL, Winstanley D. Transient improvement in chronic psoriasis after treatment of TNF-\u03b1 blocker induced disseminated M. tuberculosis infection. J Drugs Dermatol. 2012;11:119\u201320.","journal-title":"J Drugs Dermatol."},{"key":"432_CR31","first-page":"1845","volume":"125","author":"H-Z Yang","year":"2012","unstructured":"Yang H-Z, Wang K, Jin H-Z, Gao T-W, Xiao S-X, Xu J-H, et al. Infliximab monotherapy for Chinese patients with moderate to severe plaque psoriasis: a randomized, double-blind, placebo-controlled multicenter trial. Chin Med J (Engl). 2012;125:1845\u201351.","journal-title":"Chin Med J (Engl)."},{"key":"432_CR32","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1111\/j.1365-2133.2012.11162.x","volume":"168","author":"T-F Tsai","year":"2013","unstructured":"Tsai T-F, Chiu H-Y, Song M, Chan D. A case of latent tuberculosis reactivation in a patient treated with ustekinumab without concomitant isoniazid chemoprophylaxis in the PEARL trial. Br J Dermatol. 2013;168:444\u20136.","journal-title":"Br J Dermatol."},{"key":"432_CR33","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1111\/bjd.12543","volume":"169","author":"A L\u00f3pez-Ferrer","year":"2013","unstructured":"L\u00f3pez-Ferrer A, Vilarrasa E, Gich IJ, Puig L. Adalimumab for the treatment of psoriasis in real life: a retrospective cohort of 119 patients at a single Spanish centre. Br J Dermatol. 2013;169:1141\u20137.","journal-title":"Br J Dermatol."},{"key":"432_CR34","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1111\/1346-8138.12118","volume":"40","author":"M Koga","year":"2013","unstructured":"Koga M, Terawaki S, Tatsukawa R, Fujita M, Imafuku S, Nakayama J. Development of miliary tuberculosis related to anti-tumor necrosis factor-alpha inhibitor therapy for pustular psoriasis. J Dermatol. 2013;40:476\u20137.","journal-title":"J Dermatol."},{"key":"432_CR35","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s40121-013-0003-9","volume":"2","author":"C Solovan","year":"2013","unstructured":"Solovan C, Chiticariu E. Psoriasis, anti-tumor necrosis factor therapy, and tuberculosis: report of three challenging cases and literature review. Infect Dis Ther. 2013;2:59\u201373.","journal-title":"Infect Dis Ther."},{"key":"432_CR36","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.jbspin.2012.06.022","volume":"80","author":"V Andr\u00e9","year":"2013","unstructured":"Andr\u00e9 V, Liddell C, Guimard T, Tanguy G, Cormier G. Macrophage activation syndrome revealing disseminated tuberculosis in a patient on infliximab. Joint Bone Spine. 2013;80:109\u201310.","journal-title":"Joint Bone Spine."},{"key":"432_CR37","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1111\/bjd.12404","volume":"168","author":"K Reich","year":"2013","unstructured":"Reich K, Wozel G, Zheng H, van Hoogstraten HJF, Flint L, Barker J. Efficacy and safety of infliximab as continuous or intermittent therapy in patients with moderate-to-severe plaque psoriasis: results of a randomized, long-term extension trial (RESTORE2). Br J Dermatol. 2013;168:1325\u201334.","journal-title":"Br J Dermatol."},{"key":"432_CR38","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1002\/acr.21788","volume":"65","author":"EC Hsia","year":"2013","unstructured":"Hsia EC, Cush JJ, Matteson EL, Beutler A, Doyle MK, Hsu B, et al. Comprehensive tuberculosis screening program in patients with inflammatory arthritides treated with golimumab, a human anti-tumor necrosis factor antibody, in Phase III clinical trials. Arthritis Care Res. 2013;65:309\u201313.","journal-title":"Arthritis Care Res."},{"key":"432_CR39","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1111\/jdv.12011","volume":"27","author":"AI S\u00e1nchez-Moya","year":"2013","unstructured":"S\u00e1nchez-Moya AI, Garc\u00eda-Doval I, Carretero G, S\u00e1nchez-Carazo J, Ferrandiz C, Herrera Ceballos E, et al. Latent tuberculosis infection and active tuberculosis in patients with psoriasis: a study on the incidence of tuberculosis and the prevalence of latent tuberculosis disease in patients with moderate-severe psoriasis in Spain. BIOBADADERM registry. J Eur Acad Dermatol Venereol. 2013;27:1366\u201374.","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"432_CR40","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1093\/qjmed\/hct174","volume":"107","author":"A-B Mongey","year":"2014","unstructured":"Mongey A-B, Doran JP, Kleinerova J, Fitzgerald O, McDonnell TJ. Late onset tuberculosis infection in patients receiving anti-TNF\u03b1 therapy. QJM. 2014;107:69\u201371.","journal-title":"QJM."},{"key":"432_CR41","doi-asserted-by":"crossref","unstructured":"Luqu\u00edn N, Masi\u00e1 M, Noguera R, Guti\u00e9rrez F. Anal tuberculosis complicating anti-TNF\u03b1 therapy. BMJ Case Rep. 2014;2014.","DOI":"10.1136\/bcr-2014-206976"},{"key":"432_CR42","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1684\/ejd.2014.2386","volume":"24","author":"E Errichetti","year":"2014","unstructured":"Errichetti E, Piccirillo A. Latent tuberculosis reactivation in a patient with erythrodermic psoriasis under treatment with ustekinumab and a low dose steroid, despite isoniazid chemoprophylaxis. Eur J Dermatol. 2014;24:508\u20139.","journal-title":"Eur J Dermatol."},{"key":"432_CR43","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1111\/ajd.12053","volume":"55","author":"A Gin","year":"2014","unstructured":"Gin A, Dolianitis C. Multidrug resistant miliary tuberculosis during infliximab therapy despite tuberculosis screening. Australas J Dermatol. 2014;55:140\u20131.","journal-title":"Australas J Dermatol."},{"key":"432_CR44","doi-asserted-by":"publisher","first-page":"e000044","DOI":"10.1136\/rmdopen-2014-000044","volume":"1","author":"X Mariette","year":"2015","unstructured":"Mariette X, Vencovsky J, Lortholary O, Gomez-Reino J, de Longueville M, Ralston P, et al. The incidence of tuberculosis in patients treated with certolizumab pegol across indications: impact of baseline skin test results, more stringent screening criteria and geographic region. RMD Open. 2015;1:e000044.","journal-title":"RMD Open."},{"key":"432_CR45","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1111\/ijd.12679","volume":"54","author":"C Medina-Gil","year":"2015","unstructured":"Medina-Gil C, Dehesa L, Vega A, Kerdel F. Prevalence of latent tuberculosis infection in patients with moderate to severe psoriasis taking biologic therapies in a dermatologic private practice in Miami, Florida. Int J Dermatol. 2015;54:846\u201352.","journal-title":"Int J Dermatol."},{"key":"432_CR46","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1111\/ijd.12628","volume":"54","author":"T Ergun","year":"2015","unstructured":"Ergun T, Seckin D, Baskan Bulbul E, Onsun N, Ozgen Z, Unalan P, et al. The risk of tuberculosis in patients with psoriasis treated with anti-tumor necrosis factor agents. Int J Dermatol. 2015;54:594\u20139.","journal-title":"Int J Dermatol."},{"key":"432_CR47","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1111\/1346-8138.13409","volume":"43","author":"A Asahina","year":"2016","unstructured":"Asahina A, Torii H, Ohtsuki M, Tokimoto T, Hase H, Tsuchiya T, et al. Safety and efficacy of adalimumab treatment in Japanese patients with psoriasis: results of SALSA study. J Dermatol. 2016;43:1257\u201366.","journal-title":"J Dermatol."},{"key":"432_CR48","doi-asserted-by":"crossref","unstructured":"Gilbert KEGE, Manalo IF, Wu JJ. Active tuberculosis in a psoriasis patient treated with tumor necrosis factor inhibitors despite an initial negative tuberculin skin test and no known risk factors. Dermatol Online J. 2016;22.","DOI":"10.5070\/D3228032186"},{"key":"432_CR49","doi-asserted-by":"publisher","first-page":"414","DOI":"10.3109\/09546634.2016.1151857","volume":"27","author":"J Cata\u00f1o","year":"2016","unstructured":"Cata\u00f1o J, Morales M. Isoniazid toxicity and TB development during biological therapy of patients with psoriasis in Colombia. J Dermatol Treat. 2016;27:414\u20137.","journal-title":"J Dermatol Treat."},{"key":"432_CR50","doi-asserted-by":"publisher","first-page":"e115","DOI":"10.1111\/ijd.13047","volume":"55","author":"L Selvarajah","year":"2016","unstructured":"Selvarajah L, Choon SE, Tarekh NA, Chhetri AD. Cerebral tuberculoma with pulmonary tuberculosis in a patient with psoriasis treated with adalimumab, an anti-tumor necrosis factor-\u03b1 agent. Int J Dermatol. 2016;55:e115\u20137.","journal-title":"Int J Dermatol."},{"key":"432_CR51","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1111\/jdv.13633","volume":"30","author":"E Guinard","year":"2016","unstructured":"Guinard E, Bulai Livideanu C, Barth\u00e9l\u00e9my H, Viguier M, Reguiai Z, Richard MA, et al. Active tuberculosis in psoriasis patients treated with TNF antagonists: a French nationwide retrospective study. J Eur Acad Dermatol Venereol. 2016;30:1336\u201341.","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"432_CR52","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.jdcr.2017.02.001","volume":"3","author":"M Lynch","year":"2017","unstructured":"Lynch M, Roche L, Horgan M, Ahmad K, Hackett C, Ramsay B. Peritoneal tuberculosis in the setting of ustekinumab treatment for psoriasis. JAAD Case Rep. 2017;3:230\u20132.","journal-title":"JAAD Case Rep."},{"key":"432_CR53","doi-asserted-by":"crossref","unstructured":"Conti A, Piaserico S, Gisondi P, Odorici G, Galdo G, Lasagni C, et al. Management of long-term therapy with biological drugs in psoriatic patients with latent tuberculosis infection in real life setting. Dermatol Ther. 2017;30.","DOI":"10.1111\/dth.12503"},{"key":"432_CR54","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/jdv.13746","volume":"31","author":"L Cai","year":"2017","unstructured":"Cai L, Gu J, Zheng J, Zheng M, Wang G, Xi L-Y, et al. Efficacy and safety of adalimumab in Chinese patients with moderate-to-severe plaque psoriasis: results from a phase 3, randomized, placebo-controlled, double-blind study. J Eur Acad Dermatol Venereol. 2017;31:89\u201395.","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"432_CR55","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","volume":"76","author":"K Reich","year":"2017","unstructured":"Reich K, Armstrong AW, Foley P, Song M, Wasfi Y, Randazzo B, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017;76:418\u201331.","journal-title":"J Am Acad Dermatol."},{"key":"432_CR56","doi-asserted-by":"crossref","unstructured":"Giollo A, Carletto A, Tonetta S, Del Bravo P, Rossini M. Tuberculosis infection despite isoniazid prophylaxis in a patient with psoriatic arthritis treated with etanercept. J Clin Rheumatol. 2017.","DOI":"10.1097\/00124743-900000000-99398"},{"key":"432_CR57","doi-asserted-by":"crossref","unstructured":"Huang T-H, Wei Y-C, Lan C-CE. QuantiFERON\u00ae-TB Gold test conversion in a psoriatic patient with pleural tuberculosis one year after adalimumab treatment. Kaohsiung J Med Sci. 2018;34:179\u201380.","DOI":"10.1016\/j.kjms.2017.11.001"},{"key":"432_CR58","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1080\/09546634.2018.1443198","volume":"29","author":"EB Lee","year":"2018","unstructured":"Lee EB, Amin M, Man J, Egeberg A, Wu JJ. Rates of latent tuberculosis infection in patients treated with TNF inhibitors for psoriasis: a retrospective chart review. J Dermatol Treat. 2018;29:671\u20135.","journal-title":"J Dermatol Treat."},{"key":"432_CR59","doi-asserted-by":"publisher","first-page":"e185","DOI":"10.1111\/jdv.14760","volume":"32","author":"MMS Nico","year":"2018","unstructured":"Nico MMS, Gavioli CFB, Dabronzo MLD, Romiti R, Takahashi MD, Louren\u00e7o SV. The many faces of tuberculosis of the oral mucosa - three cases with distinct pathomechanisms. J Eur Acad Dermatol Venereol. 2018;32:e185\u20136.","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"432_CR60","doi-asserted-by":"crossref","first-page":"205","DOI":"10.4103\/ijdvl.IJDVL_163_17","volume":"84","author":"WM Mandy Chan","year":"2018","unstructured":"Mandy Chan WM, Oon HH, Chong W-S. Clinical experience of adalimumab in the treatment of psoriasis\u2014a 10-year journey in a tertiary dermatology centre. Indian J Dermatol Venereol Leprol. 2018;84:205\u20138.","journal-title":"Indian J Dermatol Venereol Leprol."},{"key":"432_CR61","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1111\/ijd.14066","volume":"58","author":"J-Y Bae","year":"2019","unstructured":"Bae J-Y, Lee J-I, Kim H-L, Suh H-Y, Jung H-J, Park M-Y, et al. Disseminated tuberculosis following adalimumab treatment in psoriasis despite negative screening. Int J Dermatol. 2019;58:98\u2013100.","journal-title":"Int J Dermatol."},{"key":"432_CR62","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1177\/0300060518771273","volume":"46","author":"E Dantes","year":"2018","unstructured":"Dantes E, Tofolean DE, Fildan AP, Craciun L, Dumea E, Tofolean IT, et al. Lethal disseminated tuberculosis in patients under biological treatment\u2014two clinical cases and a short review. J Int Med Res. 2018;46:2961\u20139.","journal-title":"J Int Med Res."},{"key":"432_CR63","first-page":"683","volume":"53","author":"Centers for Disease Control and Prevention (CDC)","year":"2004","unstructured":"Centers for Disease Control and Prevention (CDC). Tuberculosis associated with blocking agents against tumor necrosis factor-alpha\u2013California 2002\u20132003. MMWR Morb Mortal Wkly Rep. 2004;53:683\u20136.","journal-title":"MMWR Morb Mortal Wkly Rep."},{"key":"432_CR64","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-19132-4","volume-title":"Tuberculosis in adults and children","author":"D Heemskerk","year":"2015","unstructured":"Heemskerk D, Caws M, Marais B, Farrar J. Tuberculosis in adults and children. London: Springer; 2015."},{"key":"432_CR65","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1056\/NEJMoa011110","volume":"345","author":"J Keane","year":"2001","unstructured":"Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001;345:1098\u2013104.","journal-title":"N Engl J Med."},{"key":"432_CR66","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/sj.jidsymp.5650031","volume":"12","author":"RS Wallis","year":"2007","unstructured":"Wallis RS. Reactivation of latent tuberculosis by TNF blockade: the role of interferon gamma. J Investig Dermatol Symp Proc. 2007;12:16\u201321.","journal-title":"J Investig Dermatol Symp Proc."},{"key":"432_CR67","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.eimc.2009.05.012","volume":"28","author":"A Lalvani","year":"2010","unstructured":"Lalvani A, Pareek M. Interferon gamma release assays: principles and practice. Enferm Infecc Microbiol Clin. 2010;28:245\u201352.","journal-title":"Enferm Infecc Microbiol Clin."},{"key":"432_CR68","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1128\/CMR.00034-13","volume":"27","author":"M Pai","year":"2014","unstructured":"Pai M, Denkinger CM, Kik SV, Rangaka MX, Zwerling A, Oxlade O, et al. Gamma interferon release assays for detection of Mycobacterium tuberculosis infection. Clin Microbiol Rev. 2014;27:3\u201320.","journal-title":"Clin Microbiol Rev."},{"key":"432_CR69","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1136\/ard.2009.118935","volume":"69","author":"WG Dixon","year":"2010","unstructured":"Dixon WG, Hyrich KL, Watson KD, Lunt M, Galloway J, Ustianowski A, et al. Extended report: drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis. 2010;69:522.","journal-title":"Ann Rheum Dis."},{"key":"432_CR70","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s40257-017-0274-0","volume":"18","author":"D H\u00e4gg","year":"2017","unstructured":"H\u00e4gg D, Sundstr\u00f6m A, Eriksson M, Schmitt-Egenolf M. Severity of psoriasis differs between men and women: a study of the clinical outcome measure Psoriasis Area and Severity Index (PASI) in 5438 Swedish register patients. Am J Clin Dermatol. 2017;18:583\u201390.","journal-title":"Am J Clin Dermatol."},{"key":"432_CR71","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.jbspin.2010.12.004","volume":"78","author":"L Baronnet","year":"2011","unstructured":"Baronnet L, Barnetche T, Kahn V, Lacoin C, Richez C, Schaeverbeke T. Incidence of tuberculosis in patients with rheumatoid arthritis. A systematic literature review. Joint Bone Spine. 2011;78:279\u201384.","journal-title":"Joint Bone Spine."},{"key":"432_CR72","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2249.2010.04146.x","volume":"161","author":"J Harris","year":"2010","unstructured":"Harris J, Keane J. How tumour necrosis factor blockers interfere with tuberculosis immunity. Clin Exp Immunol. 2010;161:1\u20139.","journal-title":"Clin Exp Immunol."},{"key":"432_CR73","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3899\/jrheum.140102","volume":"91","author":"F Cantini","year":"2014","unstructured":"Cantini F, Niccoli L, Goletti D. Adalimumab, etanercept, infliximab, and the risk of tuberculosis: data from clinical trials, national registries, and postmarketing surveillance. J Rheumatol Suppl. 2014;91:47\u201355.","journal-title":"J Rheumatol Suppl."},{"key":"432_CR74","doi-asserted-by":"crossref","unstructured":"Romiti R, Valenzuela F, Chouela EN, Xu W, Pangallo B, Moriarty SR, et al. Prevalence and outcome of latent tuberculosis in patients receiving ixekizumab: integrated safety analysis from 11 clinical trials of patients with plaque psoriasis. Br J Dermatol. 2019.","DOI":"10.1111\/bjd.17604"},{"key":"432_CR75","doi-asserted-by":"publisher","first-page":"e152","DOI":"10.1038\/cti.2017.34","volume":"6","author":"M Kamm\u00fcller","year":"2017","unstructured":"Kamm\u00fcller M, Tsai T-F, Griffiths CE, Kapoor N, Kolattukudy PE, Brees D, et al. Inhibition of IL-17A by secukinumab shows no evidence of increased Mycobacterium tuberculosis infections. Clin Transl Immunol. 2017;6:e152.","journal-title":"Clin Transl Immunol."},{"key":"432_CR76","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jaad.2018.06.056","volume":"80","author":"SB Kaushik","year":"2019","unstructured":"Kaushik SB, Lebwohl MG. Psoriasis: which therapy for which patient: focus on special populations and chronic infections. J Am Acad Dermatol. 2019;80:43\u201353.","journal-title":"J Am Acad Dermatol."}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-019-00432-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40257-019-00432-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-019-00432-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T13:42:30Z","timestamp":1663162950000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40257-019-00432-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,27]]},"references-count":76,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["432"],"URL":"https:\/\/doi.org\/10.1007\/s40257-019-00432-y","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,27]]},"assertion":[{"value":"27 March 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The data have not been previously presented.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No funding was received for this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"IS, EB, ESC, TA, DS, EH and LP report no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}